Stage III Breast Cancer Active Not Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

DBCOND0031775 (Stage III Breast Cancer)Active Not Recruiting2 IdentifierTitlePurposeDrugs
NCT02971761Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerTreatment
NCT03044730Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by SurgeryTreatment